Impel Pharmaceuticals Inc. (IMPL) Misses Q2 EPS by 31c

Impel Pharmaceuticals Inc. (NASDAQ: IMPL) reported Q2 EPS of ($1.31), $0.31 worse than the analyst estimate of ($1.00). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $5.81 million.

For earnings history and earnings-related data on Impel Pharmaceuticals Inc. (IMPL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c